Back to search results

Methenamine Hippurate After BOTOX-A for Overactive Bladder

This study is comparing two ways to prevent urinary tract infections (UTIs) in women who receive BOTOX-A injections for overactive bladder (OAB). You would be randomly assigned to receive either methenamine hippurate (a non-antibiotic medicine) or a commonly prescribed oral antibiotic after your BOTOX-A injection. The main goal is to see if methenamine hippurate is just as good as antibiotics at preventing UTIs within 30 days of the procedure. We also want to understand how satisfied patients are with their assigned medication. This study is for women aged 18 or older who are getting BOTOX-A injections for OAB in a doctor's office. The current recruitment status is unclear.

Study design
This is an interventional study where 164 women will be randomly assigned to one of two treatment groups: methenamine hippurate or a standard antibiotic. The study aims to see if methenamine hippurate is not worse than antibiotics in preventing UTIs.
What's involved
You would take a medication (either methenamine hippurate or a standard antibiotic) after your BOTOX-A injection. Your UTI rates will be checked for 30 days after the procedure, and you will complete a satisfaction survey at the end of this period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 30 days after the BOTOX-A injection to measure UTI rates and assess medication satisfaction.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06953271

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

Recruiting
PHASE4Ages 18+InterventionalPrevention
Women and Infants Hospital of Rhode Island
~164 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Methenamine HippurateTypically prescribed oral antibiotic prophylaxis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acute Urinary Tract Infection
Measured over Date of the BOTOX-A injection to 30 days after the procedure

Conditions

Overactive Bladder (OAB)
Urinary Tract Infection (Diagnosis)

Explore related trials

Overactive Bladder

Where it's being run

1 sites across 1 states
Rhode Island1

Study leadership

  • Vivian Sung, MD, MPH · PRINCIPAL_INVESTIGATOR · Women & Infants Hospital

Who to contact

Colin Russell, MD, MPH
[email protected]
401-453-7560
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
undergoing intradetrusor BOTOX-A injections in the office setting for overactive bladder

Exclusion

cisgender male individuals
neurogenic reasons for bladder symptoms (i.e. spinal cord injury, multiple sclerosis, etc.)
known allergy and/or contraindication to methenamine hippurate
currently already taking methenamine hippurate at the time of the procedure
taking antibiotics for any reason on the day of their BOTOX-A procedure
positive UTI at time of procedure (positive dip at time of procedure)
history of bladder cancer
history of pelvic radiation
surgically altered detrusor muscle
pre-procedural need for catheterization
diagnosis of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
pregnant or lactating individuals

What this trial measures

  • Acute Urinary Tract InfectionDate of the BOTOX-A injection to 30 days after the procedure

    Presence of a urinary tract infection (UTI) within 30 days from intradetrusor BOTOX-A injection. UTI will be defined as positive lower urinary tract symptoms (dysuria, hematuria, and/or worsened urinary urgency or frequency) and a positive urine culture.